Prime medicine and cimeio therapeutics announce research collaboration to develop prime edited shielded-cell & immunotherapy pairs™ for genetic diseases, acute myeloid leukemia and myelodysplastic syndrome

-- collaboration combines prime medicine's prime editing platform with cimeio therapeutics' shielded cell and immunotherapy pairs™ (scip™) platform -- -- aim to reduce toxicity of conditioning regimens and introduce new therapeutic options that can expand the utility of hematopoietic stem cell (hsc) transplant and in vivo genetic therapies --
PRME Ratings Summary
PRME Quant Ranking